Taking a daily low-dose aspirin for several years increases the risk of serious bleeding in healthy older adults by about 24%, and this risk is not offset by any meaningful reduction in heart attacks or strokes.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review and meta-analysis of all randomized trials of low-dose aspirin for primary prevention in adults aged 70+ would definitively quantify the net balance of major hemorrhage risk versus cardiovascular event reduction across diverse populations.
A systematic review and meta-analysis of all published and unpublished randomized controlled trials comparing daily low-dose aspirin (75–100 mg) versus placebo in adults aged 70 or older without prior cardiovascular disease, with standardized definitions of major hemorrhage (intracranial, GI, or other clinically significant bleeding) and MACE (non-fatal MI, ischemic stroke, cardiovascular death), pooling individual participant data from trials with minimum 5-year follow-up and adjusting for age, sex, and comorbidities.
A new RCT could confirm whether the 24% increased hemorrhage risk persists across different dosages, formulations, or subpopulations of older adults with varying baseline bleeding risks.
A double-blind, placebo-controlled RCT of 10,000 adults aged 70–80 with no prior CVD, randomized to 100 mg enteric-coated aspirin or placebo daily for 7 years, with primary outcome being time to first major hemorrhage (defined as requiring transfusion, hospitalization, or causing death), secondary outcomes including MACE, all-cause mortality, and adherence monitored via pill counts and biomarkers.
A large prospective cohort could assess whether the hemorrhage risk varies by baseline biomarkers (e.g., platelet reactivity, lipoprotein(a)) or genetic factors in older adults taking aspirin.
A prospective cohort of 20,000 adults aged 70+ initiating low-dose aspirin for primary prevention, with annual blood sampling for platelet function, inflammatory markers, and genetic variants, linked to national health registries to track hemorrhage events over 10 years, adjusting for anticoagulant use, NSAID intake, and hypertension control.
A case-control study could identify whether specific subgroups (e.g., those with prior GI ulcers or low hemoglobin) have disproportionately higher hemorrhage risk when taking aspirin.
A nested case-control study within a primary care database, comparing 1,000 older adults with major hemorrhage to 3,000 matched controls without hemorrhage, assessing prior aspirin use (dose, duration, formulation), concomitant medications, and comorbidities, with exposure data validated via pharmacy records and medical charts.
A cross-sectional survey could estimate the prevalence of aspirin use and concurrent bleeding symptoms in community-dwelling older adults, but cannot determine causation.
A national survey of 5,000 adults aged 70+ measuring self-reported aspirin use, recent bruising, nosebleeds, or melena, alongside hemoglobin levels and medication lists, to estimate association between aspirin use and bleeding symptoms at a single time point.